Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02660788
Other study ID # H12-02832
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2013
Est. completion date December 2015

Study information

Verified date September 2021
Source British Columbia Cancer Agency
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, double-blinded study conducted in British Columbia, Canada, where there is a publicly funded, organized screening program and screening mammography is recommended at 24-month intervals. Eligible women aged 51-73 years old and overdue for their screening mammogram by 6-24 months are identified in the database of the Screening Mammography Program of BC (SMPBC). Family physicians are recruited by mail and asked to sign letters to the overdue women in their practices. The overdue women are randomized and mailed either the signed reminder letter and the standard reminder postcard, or the standard reminder postcard alone. The primary endpoint is the proportion of overdue women attending a screening mammogram appointment 6 months after the mailing.


Recruitment information / eligibility

Status Completed
Enrollment 5498
Est. completion date December 2015
Est. primary completion date December 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 51 Years to 73 Years
Eligibility Inclusion Criteria: Active family physicians (family physicians, general practitioners or primary care physicians) who have overdue women in their practice that meet the following criteria: - Previously been enrolled in the SMPBC and had a previous normal screening mammogram. - Have agreed to being contacted for research on the SMPBC questionnaire - Are 6-24 months overdue from their last screening mammogram - Live in BC - Have listed an active family physician as the contact to receive their mammography results Exclusion Criteria: - Family physicians who do not work in primary care - Family physicians who do not have overdue women in their practice

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Standard Reminder Postcard

Family Physician Reminder Letter


Locations

Country Name City State
Canada BC Cancer Agency Vancouver British Columbia

Sponsors (2)

Lead Sponsor Collaborator
British Columbia Cancer Agency Canadian Breast Cancer Foundation

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Chan EK, Wilson C, Tyldesley S, Olivotto IA, Lai A, Sam J, Harry R, Nichol A. Signed family physician reminder letters to women overdue for screening mammography: A randomized clinical trial. J Med Screen. 2018 Sep;25(3):149-154. doi: 10.1177/096914131771 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Overdue Women Returning for Screening Mammography Percentage of overdue women returning for screening mammography, measured from the date of randomization 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2